Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Alzheimer’s Drugs Market Forecast: Value Set To Climb From $10.98 Billion To $15.39 Billion
The alzheimer’s drugs market has experienced substantial growth in recent years. It is anticipated to expand from $10.09 billion in 2025 to $10.99 billion in 2026, at a compound annual growth rate (CAGR) of 8.9%. This historical expansion can be attributed to an increasing elderly population, the rising prevalence of Alzheimer’s disease, growing awareness surrounding dementia care, the limited treatment options available in earlier periods, and advancements in neuroscience research.
The Alzheimer’s drugs market size is anticipated to undergo significant growth in the upcoming years. This sector is expected to expand to $15.4 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This expansion over the forecast period can be attributed to various factors such as advancements in precision medicine, the integration of AI in drug development, an increase in healthcare infrastructure, governmental support and funding allocated to dementia research, and the rise of digital health monitoring solutions. Dominant trends during this period include the development of personalized Alzheimer’s therapies, innovations in neuroprotective drugs, improved early diagnosis and screening solutions, the introduction of combination and multi-target drugs, and enhanced patient adherence and monitoring solutions.
Get A Free Sample Report With In-Depth Market Insights:
Alzheimer’s Drugs Market Demand Drivers Opening New Revenue Streams
The escalating occurrence of Alzheimer’s disease is projected to fuel the expansion of the Alzheimer’s drugs market. This neurological condition progressively deteriorates, causing brain shrinkage and cell death over time. Medications designed for Alzheimer’s disease are utilized to manage memory impairment, cognitive challenges in thinking and reasoning, and difficulties in performing daily tasks. These drugs play a role in enhancing patients’ quality of life and helping them maintain independence. A notable illustration comes from a May 2024 report by the Alzheimer’s Association, a US-based nonprofit organization committed to Alzheimer’s care, support, and research, which revealed that the count of Americans aged 65 and older diagnosed with Alzheimer’s dementia grew from 6.5 million in 2022 to an estimated 6.9 million in 2024. Thus, the rising incidence of Alzheimer’s disease is significantly propelling the growth of the Alzheimer’s drugs market.
Alzheimer’s Drugs Market Segment Analysis Spotlighting Growth Areas
The alzheimer’s drugs market covered in this report is segmented –
1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Early To Moderate Stages, Moderate To Severe Stages
Alzheimer’s Drugs Market Trends Powering Strategic Industry Growth
Leading companies within the Alzheimer’s drugs market are engaged in the development of innovative products, including amyloid plaque-targeting therapy, aiming to advance treatment options and improve patient outcomes. Amyloid plaque-targeting therapy represents a treatment strategy for Alzheimer’s disease that focuses on either decreasing or preventing the buildup of amyloid-beta plaques within the brain. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical company, secured approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency responsible for safeguarding public health. Kisunla (donanemab-azbt) holds the distinction of being the first and only amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease. Its mechanism involves assisting the body in clearing excess amyloid plaques from the brain, which are correlated with cognitive decline in Alzheimer’s patients. Kisunla is administered through an intravenous infusion every four weeks. The initial dosing regimen consists of 700 mg for the first three doses, subsequently increasing to 1400 mg. Kisunla is specifically indicated for adults presenting with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, provided they have confirmed amyloid pathology.
Alzheimer’s Drugs Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the alzheimer’s drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.
View The Full Alzheimer’s Drugs Market Report:
Alzheimer’s Drugs Market Regional Analysis And Leading Geography
North Americawas the largest region in the Alzheimer’s drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer’s drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
